에이비엘바이오

298380KOSDAQ기초 의약물질 제조업

54.6 / 100

Reference Date: 2026-07-24

Financial Score22.0 / 40

News Sentiment19.6 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Plunged 24.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

ABL Bio focuses on a growth-oriented business model through technology licensing (License-out) and joint development based on its dual-antibody platform 'Grabody™'. The company addresses unmet medical needs with global technology transfer cases in areas such as ADCs and immuno-oncology therapies. Its U.S. subsidiary, NEOK Bio, manages ADC clinical trials, and cash inflows from milestone achievements in licensing agreements enhance financial stability.

Number of Employees

108people

Average Salary

125.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 25.444.0Point

PBR

—Industry Average 1.263.5Point

ROE

-23.38Industry Average -6.033.5Point

3.9x industry avg (excellent)

Debt Ratio

0.47Industry Average 6.628.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲44.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼1068.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -24.4% (declining, 3yr)

Detailed News Sentiment

15 totalPositive 11Neutral 2Negative 2Average Sentiment Score 78.3

Positive
인투셀, 삼성에피스 파트너십 '첫 수확'…"연내 자체 임상 성과도 기....
인투셀과 삼성바이오에피스의 파트너십으로 인해 특허 논란에 대한 시장 우려가 해소되고, 연내 임상 결과 발표와 기술이전 가속화가 예상되어 에이비엘바이오의 긍정적 전망이 강화되었다.
Positive
에이프릴바이오, 외부 에셋으로 RNA 시장 진입…'AOC' 확장에 주목
에이프릴바이오가 새로운 RNA 이중타깃 siRNA 물질을 도입하여 대사질환 중심의 AOC 시장에서 경쟁력을 강화하고 있다.
Negative
코스피 장 초반 5%대 급락…매도 사이드카 또 발동(상보)
코스피 급락으로 에이비엘바이오 주가도 큰 하락을 겪었다.

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 74,300Won52-week high 245,50052-week low 69,300

1-month return0.0Point

1m -24.80% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-07-16
Neutral투자판단관련주요경영사항(임상시험계획변경승인) (이중항체 면역항암제 ABL503의 제1상 임상시험계획 (IND) 변경승인)2026-07-09
Neutral주식등의대량보유상황보고서(일반)2026-07-06
Neutral기업설명회(IR)개최2026-07-02
Neutral기업설명회(IR)개최2026-07-02